Stifel on Summit Therapeutics plc (SMMT): 'first look, ever, at an emerging OS from an invonescimab P3 randomized against antiPD-1 (tislelizumab)'
Tweet Send to a Friend
Stifel analyst Dara Azar reiterated a Buy rating and $45.00 price target on Summit Therapeutics plc (NASDAQ: SMMT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
